Q3 revenue growth rate dropped to 1%. Can the next approved botox product in China be partnered with imeik technology development? | Interpretations

1. imeik technology development's performance in the first three quarters has shown some growth, but the growth rates of revenue and net income attributable to the parent have slowed down. 2. In search of new performance growth points, imeik technology development's research and development expenses continue to rise, laying out in areas such as weight management drugs and botulinum toxin.

cls.cnOct 23 23:43

imeik technology development Q3 revenue increased by 1.10% year-on-year, net income increased by 2.13% | Financial Report Watch

In the first three quarters, the company achieved revenue of approximately 2.376 billion yuan, a year-on-year increase of 9.46%; net income was approximately 1.586 billion yuan, a year-on-year increase of 11.79%. The operational scale of the company is steadily increasing, and the profitability meets market expectations.

wallstreetcnOct 23 21:43

Revenue and net profit growth rates have both slowed down. Is Jinbo Life Sciences, which has been frequently accused, feeling the pressure? | interpretations

①In the first three quarters of this year, Jinbo Bioscience's performance still maintained a high-speed growth, but the growth rate slowed down compared to the same period last year. ②In addition, the rapid growth of the company's sales expenses was caused by reasons such as the expansion of the sales team. ③The company's core product, Weiyi Mei, is facing multiple pressures, so Jinbo Bioscience has frequently stated its posture in the face of internet-related sales platforms.

cls.cnOct 22 00:03

The performance is "double- declining" and the stock price is "constantly falling". Why did the growth engine of Bloomage Biotechnology Corporation Limited lose momentum?

bloomage biotechnology corporation limited once again experienced a phenomenon of declining revenue and net income in the first half of the year. The company achieved revenue of 2.81 billion yuan, a year-on-year decrease of 8.61%; achieved net income of 0.342 billion yuan, a year-on-year decrease of 19.51%; Although the raw materials business and medical terminal business performed well, the two new major sectors strongly promoted in recent years—functional skincare products and functional foods—have both experienced simultaneous declines in growth rate.

cls.cnAug 24 10:23

The gross margin of solution injection products has declined, and the growth rate of imeik technology development's Q2 performance has dropped to single digits|speed reading announcement

imeik technology development H1 revenue and net income growth slowed down. Solution-based injection product gross margin has declined, and its proportion in total revenue further decreased. In addition to laying out the research and development pipeline for botulinum toxin, GLP-1 drugs, the company is also further expanding in the field of medical beauty equipment.

cls.cnAug 21 22:16

Pharmaceutical Investment Indicator|The China Food and Drug Administration (CFDA) is planning to introduce new regulations for exporting pharmaceuticals. Novo Nordisk and Eli Lilly and Co's GLP-1 products sold well in the first half of the year. Bloomage

①The State Administration for Market Regulation has solicited opinions on new rules for exporting drugs; The National Health Insurance Administration has approved a list of 440 pharmaceuticals through preliminary review; ②Beigene's revenue in the first half of the year was nearly 12 billion, and Baiyuzhe's sales increased by 122% YoY; ③Novo Nordisk's semaglutide and Eli Lilly and Co's Trulicity sold nearly $13 billion and $6.7 billion respectively in the first half of the year; ④Two domestic RDN products, Meilweiye Ye and Xintong Medical, have been approved for listing.

cls.cnAug 11 17:25